GleamWall
中文EN

KURA Kura Oncology, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1422143 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-35.0%
TTM EPS YoY-33.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-394.3%
Net margin-369.3%
FCF margin-112.4%
EBITDA margin-392.5%

Returns

ROE-224.9%
ROA-48.2%
ROIC (approx.)-389.8%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets96.8%
Debt / equity0.55x
Current ratio3.60x
Interest coverage-227.12x

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-34.1%
Payout ratio—
Capex / revenue4.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$22.84M$20.87M$18.27M$17.34M$20.75M$15.29M$14.11M—
Cost of revenue$371,000$243,000$262,000—————
Gross profit$22.47M$20.63M$18.00M—————
R&D expense$66.88M$61.89M$65.26M$64.41M$67.91M$62.78M$55.97M$52.27M
SG&A expense$30.25M$31.75M$31.55M$39.14M$32.84M$25.17M$22.84M$24.07M
Operating income-$74.66M-$73.01M-$78.81M-$86.27M-$80.00M-$72.67M-$64.70M-$22.45M
Interest expense$350,000$345,000$336,000$346,000$393,000$391,000$382,000$403,000
Pretax income-$70.22M-$68.32M-$73.33M-$80.93M-$74.12M-$66.12M-$57.20M-$17.20M
Income tax$0$5,000$8,000$71,000$0$0$226,000—
Net income-$70.22M-$68.33M-$73.33M-$81.00M-$74.12M-$66.12M-$57.43M-$19.22M
EBITDA-$74.33M-$72.64M-$78.46M-$85.86M-$79.83M-$72.44M-$64.46M-$22.25M
EPS (basic)-0.78-0.77-0.83—-0.85-0.75-0.66—
EPS (diluted)-0.78-0.77-0.83—-0.85-0.75-0.66—
Weighted avg. shares (diluted)89.82M88.86M88.61M—87.64M87.59M87.42M—
Balance sheet
Cash & equivalents$57.94M$70.24M$39.08M$149.10M$95.29M$81.95M$51.27M$224.46M
Short-term investments$434.16M$448.78M$541.74M$518.14M$454.38M$548.78M$606.92M$502.93M
Receivables$14.48M$9.45M$9.35M$8.80M$35.94M$4.57M$48.75M$2.06M
Inventory$4.98M$2.48M$843,000$413,000———$0
Current assets$534.70M$559.44M$623.78M$708.66M$620.66M$660.08M$724.20M$744.83M
PP&E, net$7.46M$7.59M$7.61M$7.86M$7.40M$3.91M$2.35M$1.68M
Total assets$566.50M$587.79M$652.55M$738.36M$649.38M$682.42M$743.76M$760.16M
Current liabilities$148.73M$118.19M$101.50M$116.97M$121.30M$107.17M$89.77M$78.71M
Short-term debt$8.53M$4.22M—$0$4.34M$3.11M$1.92M$2.61M
Long-term debt$1.30M$5.57M$9.75M$9.71M$5.34M$6.51M$7.65M$6.92M
Total debt$9.83M$9.79M$9.75M$9.71M$9.67M$9.62M$9.57M$9.52M
Total liabilities$548.54M$539.36M$544.67M$564.23M$406.84M$376.94M$379.36M$346.52M
Shareholders' equity$17.96M$48.43M$107.88M$174.13M$242.54M$305.49M$364.41M$413.64M
Net debt-$48.10M-$60.45M-$29.33M-$139.39M-$85.61M-$72.33M-$41.70M-$214.94M
Shares outstanding91.87M88.95M88.76M87.86M87.02M86.80M80.78M78.23M
Cash flow statement
Operating cash flow-$54.44M-$62.55M-$85.85M$117.27M-$80.63M-$28.78M-$71.93M$269.13M
Capital expenditure$445,000$656,000$128,000$2.32M$2.57M$1.46M$292,000$372,000
Free cash flow-$54.89M-$63.20M-$85.98M$114.95M-$83.19M-$30.23M-$72.22M$268.76M
Investing cash flow$9.60M$92.21M-$24.23M-$64.60M$93.97M$58.94M-$101.41M-$94.95M
Financing cash flow$32.54M$1.50M$69,000$1.14M$0$515,000$143,000$806,000
Depreciation & amortization$329,000$369,000$355,000$403,000$164,000$224,000$241,000$204,000
Stock-based compensation$8.17M$8.21M$8.42M$11.35M$10.96M$6.95M$7.84M$8.63M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.